Brokerages Expect Myovant Sciences Ltd (NYSE:MYOV) to Announce -$0.81 Earnings Per Share

Wall Street brokerages expect Myovant Sciences Ltd (NYSE:MYOV) to announce ($0.81) earnings per share for the current quarter, according to Zacks. Zero analysts have provided estimates for Myovant Sciences’ earnings, with the lowest EPS estimate coming in at ($0.84) and the highest estimate coming in at ($0.77). Myovant Sciences posted earnings of ($1.04) per share during the same quarter last year, which suggests a positive year over year growth rate of 22.1%. The firm is scheduled to announce its next quarterly earnings report on Thursday, February 6th.

On average, analysts expect that Myovant Sciences will report full year earnings of ($3.29) per share for the current year, with EPS estimates ranging from ($3.35) to ($3.18). For the next financial year, analysts expect that the firm will report earnings of ($3.29) per share, with EPS estimates ranging from ($3.72) to ($2.51). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that follow Myovant Sciences.

Myovant Sciences (NYSE:MYOV) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.79) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.72) by ($0.07).

A number of equities analysts have recently commented on the stock. Zacks Investment Research lowered shares of Myovant Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, January 15th. Cowen reaffirmed a “buy” rating on shares of Myovant Sciences in a research note on Tuesday, November 12th. JMP Securities reaffirmed a “buy” rating and issued a $34.00 price objective on shares of Myovant Sciences in a research note on Tuesday, November 19th. ValuEngine cut shares of Myovant Sciences from a “buy” rating to a “hold” rating in a research note on Tuesday, December 3rd. Finally, Goldman Sachs Group reaffirmed a “buy” rating and issued a $20.00 price objective (up previously from $18.00) on shares of Myovant Sciences in a research note on Tuesday, November 19th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $23.46.

Shares of NYSE:MYOV traded up $0.12 during trading on Thursday, reaching $14.00. The company had a trading volume of 829,622 shares, compared to its average volume of 674,951. The company has a fifty day moving average of $15.37 and a two-hundred day moving average of $9.44. The stock has a market capitalization of $1.27 billion, a P/E ratio of -3.69 and a beta of 2.05. Myovant Sciences has a 12 month low of $4.14 and a 12 month high of $26.02. The company has a current ratio of 2.79, a quick ratio of 2.79 and a debt-to-equity ratio of 5.88.

In other news, major shareholder Sciences Ltd. Roivant purchased 3,500,000 shares of the company’s stock in a transaction on Monday, November 25th. The stock was acquired at an average price of $15.00 per share, with a total value of $52,500,000.00. Following the transaction, the insider now directly owns 44,509,411 shares of the company’s stock, valued at approximately $667,641,165. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Kim Sablich sold 2,585 shares of the stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $16.22, for a total transaction of $41,928.70. Following the sale, the insider now directly owns 64,530 shares of the company’s stock, valued at approximately $1,046,676.60. The disclosure for this sale can be found here. In the last ninety days, insiders bought 4,046,099 shares of company stock valued at $61,228,506 and sold 46,144 shares valued at $711,963. 3.68% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Myovant Sciences by 133.4% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,518 shares of the company’s stock valued at $86,000 after buying an additional 3,154 shares during the period. Tower Research Capital LLC TRC purchased a new stake in Myovant Sciences during the 2nd quarter valued at $60,000. Barclays PLC boosted its position in Myovant Sciences by 24.6% during the 3rd quarter. Barclays PLC now owns 11,317 shares of the company’s stock valued at $59,000 after buying an additional 2,234 shares during the period. Northern Trust Corp purchased a new stake in Myovant Sciences during the 2nd quarter valued at $105,000. Finally, OneAscent Financial Services LLC purchased a new stake in Myovant Sciences during the 2nd quarter valued at $172,000. 39.23% of the stock is owned by institutional investors and hedge funds.

Myovant Sciences Company Profile

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.

Recommended Story: Liquidity

Get a free copy of the Zacks research report on Myovant Sciences (MYOV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.